Sanofi, Regeneron unveil ‘blow-out’ smoker’s lung drug data
By Ludwig Burger and Juby Babu (Reuters) -Sanofi’s asthma and eczema drug Dupixent met all targets in a trial to treat “smoker’s lung”, giving a major boost to the French drugmaker’s growth prospects, but also underscoring a heavy reliance on its bestseller. In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a […]